ORTEXORTEX News
Tracking NMFC? Get live short interest, options flow, and signals on ORTEX.Sign up free →
NM
Earnings PreviewNMFC

NMFC Reports Q2 Beat, but Analyst Targets Trail the Rally

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 4 Aug 2026, 04:01

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

NMFC heads into its Q2 earnings print today having already shown its hand — and the market liked what it saw.

The most striking element of this setup is the pre-market reaction. Q2 net investment income of $0.47 per share came in ahead of the $0.44 consensus estimate, and the stock reflected it: shares jumped nearly 5% on Monday to $7.23, adding to a 5.2% weekly gain. Dividend coverage of 1.07x keeps the income thesis intact. That said, the stock is still trading at a meaningful discount to the BDC sector average, with a price-to-book multiple of 0.64x — a level that has been compressing over the past month, down roughly 12% on a 30-day basis.

The analyst community has been uniformly cautious, and the recent beat has not yet moved the needle on targets. Keefe Bruyette & Woods lowered its target to $8.00 in late July, maintaining a Market Perform rating — still nearly 11% above the current price. B. Riley and Wells Fargo have maintained Neutral and Equal-Weight ratings respectively, with targets ranging from $7.50 to $8.00. Every recent revision has been a cut. The direction of travel from the Street has been downward for the better part of a year, reflecting concerns about realized losses on portfolio exits and NAV erosion — the bear case in a nutshell. Bulls, meanwhile, point to the solid dividend coverage and an 11.8% yield that remains well-supported by NII generation.

The insider picture adds a layer of context worth noting. Chairman Steven Klinsky purchased over $5.6 million of shares across multiple tranches in early March, at prices around $8.05–$8.17 — well above Monday's close of $7.23. That concentrated buying has not yet been vindicated on a price basis, though the Q2 beat represents a step in the right direction. A director sold $612,000 worth of stock in mid-June at $7.89, a more recent and more cautious signal from within the boardroom.

Positioning in the borrow market is relaxed rather than charged. Borrow availability has loosened considerably — running near 70% relative to short interest, up sharply from early July when it compressed to around 39%. Cost to borrow has also eased, declining more than 26% over the past month to 4.3%. Options positioning skews heavily toward calls, with a put/call ratio of just 0.08, near the low end of its 52-week range and well below the 20-day average. Short interest has ticked up about 11% over the past week but remains a small absolute position. Together, the positioning looks relaxed rather than adversarial — today's print is less about surviving a short squeeze and more about whether confirmed NII strength and dividend durability can begin closing the gap between the stock and those analyst targets clustered in the $7.50–$8.00 range.

Stocks in this article

See the live data behind this article on ORTEX.

Open NMFC on ORTEX →

How this article was generated

Generated
4 Aug 2026, 04:22
Data as of
4 Aug 2026, 04:01
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsInstitutional positioningORTEX Alpha signalsRecent ORTEX notes

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.